Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025BMC CancerOpen Access

The efficacy analysis of neoadjuvant chemoimmunotherapy followed by surgery in stage III locally advanced non-small cell lung cancer: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

XYXiaojie YangYHYong HeTGTianxing Guo

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis shows neoadjuvant chemoimmunotherapy improves outcomes in stage III NSCLC, indicating potential surgical benefits.

Key Points

  • Neoadjuvant chemoimmunotherapy led to a 65% major pathological response rate in patients with stage III NSCLC.
  • The analysis included 1043 patients from 22 studies, revealing a 38% pathological complete response rate and 73% objective response rate.
  • Safety data indicated that treatment-related adverse events occurred in 84% of patients, with severe adverse events in 13%.
  • Nivolumab and pembrolizumab-based therapies provided higher major pathological response and complete response rates compared to other immune checkpoint inhibitors.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/68e02f2cf0e39f13e7fa1ff5https://doi.org/10.1186/s12885-025-14744-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Cancer statistics, 20232023 · 17,051 citations